Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

Lancet

Volumn 358, Issue 9286, 2001, Pages 983-984

  Ratjen, Felix ^a   Döring, Gerd ^b   Nikolaizik, Wilfried H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PROTEINASE; ELASTASE; EXOTOXIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERIAL COLONIZATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SPUTUM ANALYSIS; THROAT CULTURE; TREATMENT OUTCOME;

EID: 0035934545     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06124-4     Document Type: Article

References (5)

1. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus
2. Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment
3. Placebo-controlled double-blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis
4. Treatment of Pseudomonas colonisation in cystic fibrosis